Choate Represents Pulmokine in its Acquisition by XOMA Royalty

Choate represented Pulmokine, Inc. in its sale to XOMA Royalty Corporation, a leading biotechnology royalty aggregator. Pulmokine is the owner of seralutnib, a Phase 3 asset being studied for its uses in pulmonary arterial hypertension. Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A, and a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 2025. XOMA Royalty acquired all outstanding shares of Pulmokine for a cash payment at closing and will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders.